Persephone Biosciences vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Persephone Biosciences uses gut microbiome profiling and synthetic biology to develop cancer immunotherapy response predictors and novel therapeutics; founded 2017 in San Diego; received BARDA funding for microbiome-based diagnostics;
About
Persephone Biosciences is a biotechnology company founded in 2017 by Stephanie Culler and Chris Calvert and based in San Diego, California. The company focuses on decoding the human gut microbiome to develop diagnostics and therapeutics in oncology and neonatal health. Its core thesis is that the composition of a patient's microbiome significantly affects how they respond to cancer immunotherapies such as checkpoint inhibitors — a hypothesis supported by a growing body of peer-reviewed clinical research. Persephone's diagnostic platform aims to predict immunotherapy response from a patient's microbiome signature prior to treatment initiation.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.